Net Deferred Revenues (Details) (USD $)			6 Months Ended
Mar. 31, 2013	Sep. 30, 2012	Mar. 31, 2013 Royalty revenue [Member] GSK License Agreement [Member]
Deferred royalty revenue balance for the Company's sale of future Abreva royalty rights
Net deferred revenues, Beginning Balance			$ 4,049,318
Changes during the period:
Recognized as revenues during period			(1,374,832)
Net deferred revenues, Ending Balance			2,674,486
Classified and reported as:
Current portion of deferred revenues	2,557,464	2,557,464	2,557,464
Deferred revenues, net of current portion	117,022	1,491,854	117,022
Total deferred revenues			$ 2,674,486

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration